Chapter 1

AI-Driven Microbiome Profiling for Precision Management of Inflammatory Bowel Disease

S.Thagasin[a], J.Monisha[b*]

[a]*School of Pharmaceutical Sciences, Vels Institute of Science, Technology & Advanced Studies, Chennai*

[b]*Assistant Professor, Department of Pharmaceutics, SPS, Vels Institute of Science, Technology & Advanced Studies, Chennai*

** Corresponding Author: monisha.sps@vistas.ac.in*

Abstract

Inflammatory bowel disease, or IBD, comprises crohn's disease and ulcerative colitis, chronic inflammatory disorders mediated by alterations in the human microbiome. Recent studies indicate that imbalance in the microbiome significantly contributes to disease severity and treatment response in IBD patients. In the current era of next-generation sequencing and other omics-based approaches, artificial intelligence, or AI, has been successfully applied to analyze the human microbiome data to identify specific microbial patterns to aid in the diagnosis of IBD, disease classification, and prediction of treatment outcomes. In addition, non-invasive biomarker discovery through stool samples of affected individuals can be achieved, thus enabling a more precise approach to disease management in IBD patients. Though there are certain limitations in applying AI in microbiome analysis, including data variation and validation, this approach appears to be a promising area of research to improve diagnosis, disease relapse, and treatment of IBD, thus enabling a

ISBN 978-816855381-1

more precise approach to disease management in affected individuals.

Keywords: Inflammatory Bowel Disease, Artificial Intelligence, Gut Microbiome, Microbiome Profiling, Precision Medicine.

1. Introduction

Inflammatory bowel disease (IBD) is a common, long-lasting inflammatory disease of the gastrointestinal tract. It represents two major conditions: Crohn's disease (CD) and ulcerative colitis (UC). The prevalence of IBD worldwide has increased markedly over the last several decades, and this represents a substantial healthcare burden. An important aspect of IBD is thought to be the interplay of multiple and complex factors. These factors include genetic predisposition, environmental factors, and immune response (both local and systemic), as well as changes or abnormalities in the gut microbiome [1]. The human gut microbiome is critical for maintaining homeostasis of the intestines, providing metabolic function; and regulating the immune system. Many studies now indicate that there is an imbalance in the content and diversity of gut microbial ecosystems (dysbiosis) in individuals with IBD. Many studies show that individuals with IBD have reduced microbial diversity and have altered the abundance of both beneficial and pathogenic microorganisms, which leads to chronic inflammation in the intestines [2]. Metagenomics and other omics-based technologies that employ high-throughput sequencing (HTS) have enabled the detailed characterization of gut microbiota. However, this type of technology produces vast amounts of complex data that require the use of sophisticated and advanced computational tools to interpret. Algorithms that involve artificial intelligence (AI) and machine

learning (ML) represent potentially useful tools in the analysis of microbiome data and to identify micro-biotic signatures associated with disease [3]. Through the use of Artificial Intelligence (AI), researchers are developing new methods to diagnose and classify disease in inflammatory bowel disease (IBD) through the development of novel AI-driven methods to create microbiome profiles. Through combining both microbiome characteristics with strict clinical and molecular evaluation data, multiple microbe populations can be evaluated as potential targets for creating personalized medical therapies. By developing these microbial profiles, as well as the potential responses of patients to current treatments, precision medicine approaches can be developed to improve the patient's overall experience with IBD [4].

2. Pathogenesis of inflammatory bowel disease

The gastrointestinal tract has chronic inflammation, which leads to the development of a condition known as inflammatory bowel disease (IBD). IBD contains both Crohn's disease and ulcerative colitis. The cause of IBD is complicated because there are many factors that can contribute to it. These factors include genetic risk to developing the illness, external influences, the immune system, problems with protection from infection within the intestines, and differences in the intestinal bacteria (5). Having an inherited genetic predisposition to developing IBD is critical to the development of the disease. Many genome-wide association studies have been performed that have identified many potential "susceptibility" genes that may affect how our bodies respond to the bacteria we are exposed to on a daily basis, i.e., how our bodies will protect themselves from bacterial infection (6). Antibiotics, diet, smoking, stress, and whether or not you have been exposed to an infection are all examples of external

ISBN 978-816855381-1

environmental influences that may influence both the composition and the function of the gut bacteria. For individuals who have an inherited genetic predisposition to develop IBD, these external environmental factors have the potential to disrupt the normal balance present in the intestines and activate inflammation (7).

3. Role of gut microbiome in inflammatory bowel disease

The gut microbiome plays a vital role in regulating the health of the intestine and the balance of immunity. The intestinal tract of humans is home to a diverse array of microorganisms that aid in digestion and metabolism as well as provide a barrier to the entry of pathogens. Healthy individuals have a healthy interaction with their microbes, which aids in holding the immune system and epithelial barrier of the intestines in balance (8).Dysregulated gut microbial composition can be found in inflammatory bowel disease (IBD) patients. Microbial dysbiosis refers to an imbalance of factors that leads to decreased diversity of the multiple microbial communities and increased relative abundance of both good and bad bacteria. For instance, studies show that levels of Faecalibacterium prausnitzii are often low in IBD patients, while potentially pathogenic bacteria are significantly increased. These changes to the gut microbiome may lead to increased intestinal inflammation and contribute to the overall progression of the disease (9). The gut microbiome is also a significant regulator of immune responses occurring within the intestine. Commensal microorganisms interact with epithelial cells and immune cells, leading to immune tolerance and maintenance of a balanced immune response. When this balance is broken, abnormal immune activation may occur, which may lead to the production of pro-inflammatory cytokines and to chronic inflammation of the intestinal mucosa. Additionally, beneficial gut microbiota are able to

produce multiple compounds that promote a healthy immune response. (10)

4. Microbiome analysis technique

Sequencing technologies have made great strides in understanding the gut microbiome of patients with inflammatory bowel disease. Some common methods used to analyze the gut microbiome include 16S rRNA gene sequencing, whole-genome shotgun metagenomics, metatranscriptomics, metabolomics, and metaproteomics. Of these, 16S rRNA gene sequencing is used most often to identify the composition of the bacterial community, whereas shotgun metagenomics is used to gain detailed information about microbial genes and their functional pathways. Metatranscriptomics allows us to study how microorganisms express their genes, and metabolomics allows us to identify the metabolic products of microorganisms that play a role in interactions between hosts and their gut microbiomes. These different methods of analysis generate large datasets that provide researchers with a better understanding of what changes occur in the gut microbiome when dysbiosis persists, how immune function is altered, and how metabolism is affected as patients with IBD progress through their disease. By integrating the data generated from all of these different types of analyses, we have been able to develop a more comprehensive understanding of the diversity of microorganisms present in the gut microbiome and how they are functionally altered in IBD. Additionally, this research has helped lay a foundation for developing precision diagnostics and therapies for IBD. (11)

ISBN 978-816855381-1

5. Ai-driven microbiome profiling for precision management

Using artificial intelligence to examine the microbiome offers many new insights into disease states and treatment. AI can identify unique and previously unknown microbes associated with inflammatory bowel disease (IBD) and reveal potential targets for treatments. Utilizing machine learning will provide valuable data from multiple sources, allowing for more comprehensive analyses of microbial dysfunction related to IBD, such as changes in disease state, inflammatory markers, and response to therapy. Models based on AI can provide predictive information for early identification of IBD, as well as help guide a clinician's decision-making process regarding treatments that target specific microbes (i.e., probiotics, prebiotics, diet modification, or fecal microbiome transplantation). Digital models built on AI data will provide clinicians with real-time assessment of IBD severity over time; thus, AI data models will continue to help inform clinicians during the IBD treatment process by demonstrating how to tailor treatment options based on specific microbial signatures. These approaches will accelerate the move towards personalized medicine by establishing therapeutic plans according to individualized IBD-specific microbiome characteristics, ultimately improving the quality of care for IBD patients (12).

6. Challenges and Limitations

The ability of artificial intelligence (AI) to provide high-precision management of inflammatory bowel disease (IBD) could be enhanced by obtaining and analyzing the microbial profile of patients, but there are numerous limitations preventing this from happening. One major limitation is that each person has a gut microbiome with varied composition due to the influence of dietary habits, age, inherited

genes, lifestyle, and the use of medications amongst other factors, therefore making it difficult to consistently identify microbial biomarkers linked to IBD. This inherent variability in gut microbiome composition impairs the reproducibility of microbiome studies across diverse populations and locations. Moreover, there is currently no standard methodology used when conducting studies on the microbiome, which further limits our ability to use AI to help us manage IBD. Some inconsistencies that exist between the various microbiome studies are caused by variations in the sample collection process and variations in the method used to extract DNA from biological samples, as well as the sequencing platforms utilized and the data analysis pipelines used. The inconsistencies result in a difficulty when comparing and validating microbiome data among different research groups. The collection of the microbiome data represents a very complex and high-dimensional dataset; therefore, developing robust artificial intelligence/machine learning models from microbiome data is very challenging. This is due to the thousands of different microbial taxa and functional genes that microbiome data contain, therefore requiring advanced computing techniques and a considerable quantity of data to conduct analyses accurately. Unfortunately, most microbiome studies are completed with small sample sizes, making AI and ML predictive models based on these data less robust and generalizable to the population at large (13).

7. Future direction

To continue research in the area of AI-based microbiome profiling, researchers should aim to integrate microbiome data with other biological datasets, including but not limited to genomics, transcriptomics, and metabolomics in a multi-omics approach to

ISBN 978-816855381-1

elucidate how these multi-faceted mechanisms are involved with Inflammatory Bowel Disease and lead to the identification of reliable microbial biomarkers to assist with early diagnosis and treatment index. Another important area for future research will be to develop large-scale microbiome datasets, including samples collected from diverse populations in multiple geographic regions and patient groups, such that the overall size of the dataset will increase the reliability and predictive performance of the artificial intelligence (AI) and machine learning (ML) models being applied to study the microbiome. Additionally, the application of enhanced machine learning and bioinformatics tools will increase researchers' ability to analyze complex microbiome data and allow them to make superior predictions regarding disease progression, relapse risk, and treatment response for patients with IBD. The ability to analyze the microbiome data using AI may also support the development of personalized treatment options through microbiome-directed therapies such as probiotics, prebiotics, and fecal microbiota transplantation .In summary, as we continue to experience advancements in sequencing technologies, computational techniques, and cross-disciplinary teamwork, the utilization of AI-based microbiome profiling in the precision treatment of inflammatory bowel disease will only continue to improve in years to come (14).

References

1. Kaplan GG, Ng SC. Globalization of inflammatory bowel disease: perspectives from the evolution of inflammatory bowel disease in the 21st century. Nat Rev Gastroenterol Hepatol. 2017;14(5):322–333.

2. Lloyd-Price J, Arze C, Ananthakrishnan AN, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019;569(7758):655–662.

3. Topçuoglu BD, Lesniak NA, Ruffin MT, Wiens J, Schloss PD. A framework for effective application of machine learning to microbiome-based classification problems. mBio.2020;11(3):e00434-20.

4. Nishida A, Inoue R, Inatomi O, et al. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018;11(1):1–10.

5. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066–2078.

6. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474(7351):307–317.

7. Ananthakrishnan AN. Environmental risk factors for inflammatory bowel disease. Gastroenterology. 2015;149(5):1143–1160.

8. Huttenhower C, Gevers D, Knight R, et al. Structure, function, and diversity of the healthy human microbiome. Nature. 2012;486(7402):207–214.

9. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of fecal microbiota in Crohn's disease revealed by metagenomic approaches. Gut. 2006;55(2):205–211.

10. Sartor RB, Wu GD. Roles for intestinal bacteria, viruses, and fungi in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2017;152(2):327–339.

11. Integrative approaches for microbiome analysis in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol.

12. Artificial intelligence for microbiome-based precision medicine. Front Microbiol.

13. Integrative human microbiome project and advances in microbiome research. Nature, Microbiome, Briefings in Bioinformatics, Trends in Microbiology, and Frontiers in Microbiology.

14. Lloyd-Price J, Arze C, Ananthakrishnan AN, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature.2019;569(7758):655-662.

ISBN 978-816855381-1